Business
Canaquest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via WWW.CANAQUESTSTORE.COM, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via WWW.CANAQUESTSTORE.COM, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD.
About this update from Canaquest Medical Corporation
[{"type":"text","content":"USERS REPORT INCREASED MENTAL CLARITY,BETTER SLEEP, MORE ENERGY, AND LESS BRAIN FOG AND JOINT STIFFNESSTORONTO, ON / ACCESSWIRE / September 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in California for distribution across the United States and international export.Proprietary Formulation - IP protected, International Patents filed, and Pre-clinical Trial results - published in peer-reviewed European Journal of Neuroscience (Oct. 2020).New Pathway Discovery - molecules bond and synergistically attach to Peroxisome proliferator-activated receptors (PPARs) allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself did not do this in the pre-clinical trials.Mentanine® was developed by Dr. Steven Laviolette, a neuroscientist and scientific veteran with decades of research experience in the field of mental health and cannabinoids. Dr. Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.comCanaQuest has further enhanced the formulation and delivery format for maximum bioavailability.One user, a doctor, stated (without professional advice): "For the last seven years I had problems with sleeping, body pain and depression. I am so optimistic that from now and onward with Mentanine®, I have my normal happy life back.""Mentanine® effectively reaches the section of the brain that regulates emotion, such as anxiety, depression, and PTSD. We believe our scientific formulation will materially improve quality of life for people suffering from certain debilitating mental health ailments," commented Paul Ramsay, CanaQuest Medical President.Physicians, psychiatrists, healthcare practitioners, and pharmacists interested in joining our growing network can contact [email protected]...